Kellanova (NYSE:K), a biotech company, is witnessing a flurry of activity among financial advisory corporations and wealth management firms. The movement ranges from new purchases of its shares to selling considerable stakes. For instance,
Toth Financial Advisory Corp and
AMF Tjanstepension AB were cited for buying new shares. Simultaneously, entities such as
Kellogg W. K. Foundation Trust and
Brookstone Capital Management sold substantial shares.
Kellanova also trumped former Kellogg's Q1 earnings, promising as a high-ranked value stock.
Vanguard Group Inc. and
PNC Financial Services Group Inc. increased their holdings, contrarily,
Nomura Holdings Inc. and
Goldman Sachs Group Inc. decreased their position. Further,
Kellanova has received a consensus recommendation of 'Hold' from multiple brokerages. Although it outperformed the market on several occasions, it has also noted a few dips in its stocks. Among institutional owners,
Kellanova remain favourite, holding 86% stake. Despite a decline in the stock after separation from
Kellogg, experts see a potential growth prospect in
Kellanova's business model.
Kellanova Stocks K News Analytics from Tue, 25 Jul 2023 07:00:00 GMT to Sun, 30 Jun 2024 11:20:17 GMT -
Rating 4
- Innovation 2
- Information 7
- Rumor -3
